Zobrazeno 1 - 10 of 20 pro vyhledávání: '"Nathan D Pfeifer"'
1
Akademický článek
Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial
Autor: Dave Singh, Tuan Nguyen, Jacky Woo, Rajeev Saggar, Nathan D Pfeifer, David A Lombardi, Brett Haumann, John Belperio, Maxim Bogus, Valentyn Moskalenko, David L Bourdet, Elad Kaufman, Corbin G Thompson, Edmund J Moran
Publikováno v: BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Background The inhaled lung-selective pan-Janus kinase inhibitor nezulcitinib had favourable safety and potential efficacy signals in part 1 of a phase 2 trial in patients with severe COVID-19, supporting progression to part 2.Methods Part 2 was a ra
Externí odkaz: https://doaj.org/article/905da654e8a64ea59f91db7bc7d56b1d
Zobrazit plný text záznamu
2
Akademický článek
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19
Autor: Nathan D. Pfeifer, Arthur Lo, David L. Bourdet, Kenneth Colley, Dave Singh
Publikováno v: Clinical and Translational Science, Vol 14, Iss 6, Pp 2556-2565 (2021)
Abstract Nezulcitinib (TD‐0903), a lung‐selective pan–Janus‐associated kinase (JAK) inhibitor designed for inhaled delivery, is under development for treatment of acute lung injury associated with coronavirus disease 2019 (COVID‐19). This t
Externí odkaz: https://doaj.org/article/15037cc6b9a34adf8465d0c461bdbabf
Zobrazit plný text záznamu
5
A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1
Autor: Valentyn Moskalenko, Nathan D. Pfeifer, Brett Haumann, Edmund J. Moran, Elad Kaufman, Glenn Crater, David A. Lombardi, David L. Bourdet, RW Lord, Ashley Woodcock, Jacky Woo, Dave Singh, Maxim Bogus, Tuan Nguyen, Rajeev Saggar, Emily Y. Weng
BackgroundLung-targeted anti-inflammatory therapy could potentially improve outcomes in patients with COVID-19. The novel inhaled pan-Janus kinase (JAK) inhibitor TD-0903 was designed to optimise delivery to the lungs while limiting systemic exposure
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40423d33da822e5548c57baa4f6ff857
https://doi.org/10.1101/2021.03.09.21252944
Zobrazit plný text záznamu
7
Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236
Autor: Elad Kaufman, Thomas Scott, Thomas Southworth, Glenn Crater, Emma Gordon, Reuben Sana, Jacky Woo, Dave Singh, Melanie A. Kleinschek, Alexander McNamara, Edmund J. Moran, Nathan D. Pfeifer
Publikováno v: Airway pharmacology and treatment.
Introduction: Janus kinase (JAK) enzymes mediate signaling of many cytokines associated with asthma. TD-8236 is a pan-JAK inhibitor designed to maximize lung selectivity. Aims: The aim of this study was to establish methods for detection of target en
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88274f744a9d4b45638e13d320cc03d4
https://doi.org/10.1183/13993003.congress-2020.2891
Zobrazit plný text záznamu
8
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
Autor: RW Lord, Elad Kaufman, Nathan D. Pfeifer, Glenn Crater, Edmund J. Moran, Ashley Woodcock, Rajeev Saggar, Jacky Woo, Maxim Bogus, Dave Singh, David L. Bourdet, Tuan Nguyen, Emily Y. Weng, Valentyn Moskalenko, Brett Haumann, David A. Lombardi
Publikováno v: Singh, D, Bogus, M, Moskalenko, V, Lord, R, Moran, E J, Crater, G D, Bourdet, D L, Pfeifer, N D, Woo, J, Kaufman, E, Lombardi, D A, Weng, E Y, Nguyen, T, Woodcock, A, Haumann, B & Saggar, R 2021, ' A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 ', European Respiratory Journal, vol. 58, no. 4, 2100673 . https://doi.org/10.1183/13993003.00673-2021
The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus pl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d23c90bcf978bfeadaa1468946ed9e
https://doi.org/10.1183/13993003.00673-2021
Zobrazit plný text záznamu
9
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
Autor: Gerd Burmester, Robert Landewé, Ana P M Lacerda, Nupun A Varothai, Mark C. Genovese, Alan Friedman, Nathan D Pfeifer
Publikováno v: Annals of the rheumatic diseases, 76(2), 414-417. BMJ Publishing Group
BackgroundAdalimumab has been used in patients with moderately to severely active rheumatoid arthritis (RA) for over 10 years and has a well-established safety profile across multiple indications.ObjectiveTo update adverse events (AEs) of special int
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e96eb8c76bcb18def8513a1f06d4608
https://doi.org/10.1136/annrheumdis-2016-209322
Zobrazit plný text záznamu
10
Species Differences in Hepatobiliary Disposition of Taurocholic Acid in Human and Rat Sandwich-Cultured Hepatocytes: Implications for Drug-Induced Liver Injury
Autor: Kathleen Köck, Kyunghee Yang, Nathan D. Pfeifer, Kim L. R. Brouwer
Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 353:415-423
The bile salt export pump (BSEP) plays an important role in bile acid excretion. Impaired BSEP function may result in liver injury. Bile acids also undergo basolateral efflux, but the relative contributions of biliary (CLBile) versus basolateral effl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31530f8ff3c00665d30a7a656d7b9e91
https://doi.org/10.1124/jpet.114.221564
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje